Tardive dyskinesia syndromes: current concepts
References (30)
- et al.
Drug-induced tardive syndromes
Parkinsonism Relat Disord
(1999) - et al.
Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia
Neuropsychopharmacology
(2000) - et al.
Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba.
Biol Psychiatry
(2012) - et al.
Spectrum of tardive syndromes: clinical recognition and management
Postgrad Med J
(2011) Diagnostic and statistical manual of mental disorders
(2000)- et al.
Tardive dyskinesia and new antipsychotics
Curr Opin Psychiatry
(2008) - et al.
[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease
Mov Disord
(2006) - et al.
Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort
Neurology
(2012) - et al.
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
Mov Disord
(2006) - et al.
Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: A meta-analysis
Mov Disord
(2009)
Update on typical and atypical antipsychotic drugs
Annu Rev Med
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies
Am J Psychiatry
New insights into the mechanism of drug-induced dyskinesia
CNS Spectr
The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats
Psychopharmacology (Berl)
Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study
Psychopharmacology (Berl)
Cited by (87)
Tardive Syndrome Spectrum: Phenomenology, Diagnosis and Treatment
2023, Revista Colombiana de PsiquiatriaMinimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine
2022, Parkinsonism and Related DisordersCitation Excerpt :Tardive dyskinesia (TD) is a potentially debilitating movement disorder that may be caused by exposure to dopamine-receptor antagonists (DRAs), including typical and atypical antipsychotics and antiemetics [1–3].
Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia
2022, American Journal of Geriatric PsychiatryAkathisia and Restless Legs Syndrome: Solving the Dopaminergic Paradox
2021, Sleep Medicine ClinicsCitation Excerpt :Tardive akathisia is included in the tardive syndrome, a broad spectrum of DRBA-induced abnormal movements, which include tardive dyskinesia among other manifestations.5–7 The tardive syndrome has 2 main characteristics: it appears late after prolonged exposure to the DRBA, and it persists and continues, and often worsens, after the offending drug is withdrawn.6,7 Acute akathisia, on the other hand, is a condition with identical symptoms that tardive akathisia that occurs fairly early after the DRBA is introduced and dissipates upon its withdrawal.7
Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances
2019, Behavioural Brain ResearchNew insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach
2019, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :Movement disorders, both acute and chronic, are well-described adverse effects of antipsychotic (AP) drugs and significantly affect patients' quality of life (Blanchet, 2003; Margolese et al., 2005; van Harten and Tenback, 2011). Tardive dyskinesia (TD) is a chronic, often irreversible, adverse effect of long-term AP medications treatment, and is characterized by repetitive and involuntary movement in the oral and facial regions, as well as the limbs and trunk (including tics, myoclonus and choreoathetosis) (Aquino and Lang, 2014; Casey, 2004; van Harten and Tenback, 2011; Zai et al., 2018). The course of TD may be fluctuating and the diagnosis is based on clinical evaluation (van Harten and Tenback, 2011).